Study for the mechanism of triple negative breast cancer cell-derived exosomes regulating autophagy of tumor-associated fibroblasts via the s100a4-p53-beclin1 pathway

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026724

Enrollment

Unknown

Registered

2019-10-20

Start date

2019-10-25

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

experimental group and control group:N/A

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Selection object for the biopsy diagnosed preoperatively and three negative breast cancer patients after neoadjuvant therapy, patients' voluntary participation and sign the informed consent form (for fresh specimens of 8 patients with breast cancer, the patients with acquisition of informed consent and after signing for pathological section of 30 patients with breast cancer, contact patients with oral informed consent and record, if can obtain signature signed informed consent).

Exclusion criteria

Exclusion criteria: Preoperative chemoradiotherapy, non-primary breast cancer, advanced breast cancer patients, etc.

Design outcomes

Primary

Measure	Time frame
Tumor S100A4 p53 autophagy related (Beclin1 p62 LC3 PARP) and emt-related protein (vimentin fibronectin cadherin) expression levels;	—

Countries

China

Contacts

Public ContactMengchuan Wang

Zhujiang Hospital, Southern Medical University

dr.mengchuan@outlook.com+86 15989278932

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026